Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1982 Nov;50(2):318–326.

Recovery of humoral and cellular immunity by soluble mediators after 5-fluorouracil-induced immunosuppression.

V J Merluzzi, K Last-Barney, B M Susskind, R B Faanes
PMCID: PMC1536680  PMID: 6217933

Abstract

5-Fluorouracil (5-FU) administered in daily injections to mice (15-60 mg/kg; subcutaneous) was differentially toxic to helper T cells. Precursors for both antibody forming cells and cytotoxic T lymphocytes (CTL) were spared. 5-FU suppressed the in vitro T cell-dependent antibody response to sheep red blood cells (SRBC). This low response was restored to normal levels by the addition of T cell replacing factor (TRF) or mixed lymphocyte culture (MLC) supernatants to the culture system. T cell-independent antibody responses to TNP-Ficoll or TNP-LPS were not eliminated by 5-FU but, in contrast, were elevated two-four-fold. These results indicate that precursors for antibody forming cells for T cell-dependent and -independent antibody responses were not eliminated by 5-FU, 5-FU administered in the same regimen did not reduce the number of CTL precursors as shown by limiting dilution analysis, but did cause a reduction in the capacity of lymphocytes from pre-treated mice to generate a CTL response in vitro. This low CTL response was restored to control levels by adding Lyt 1+2- T cells or sources of interleukin 2 (IL2) to the culture system, indicating that 5-FU similarly eliminated helper cells for CTL precursor differentiation as well as helper cells for antibody synthesis.

Full text

PDF
318

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baum L. L., Pilarski L. M. In vitro generation of antigen-specific helper T cells that collaborate with cytotoxic T-cell precursors. J Exp Med. 1978 Dec 1;148(6):1579–1591. doi: 10.1084/jem.148.6.1579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Berenbaum M. C. Time-dependence and selectivity of immunosuppressive agents. Immunology. 1979 Feb;36(2):355–365. [PMC free article] [PubMed] [Google Scholar]
  3. Carter S. K., Goldin A. Experimental models and their clinical correlations. Natl Cancer Inst Monogr. 1977 Mar;(45):63–74. [PubMed] [Google Scholar]
  4. Cerottini J. C., Brunner K. T. Cell-mediated cytotoxicity, allograft rejection, and tumor immunity. Adv Immunol. 1974;18:67–132. doi: 10.1016/s0065-2776(08)60308-9. [DOI] [PubMed] [Google Scholar]
  5. Cheever M. A., Greenberg P. D., Fefer A. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J Immunol. 1980 Aug;125(2):711–714. [PubMed] [Google Scholar]
  6. Chused T. M., Kassan S. S., Mosier D. E. Macrophage requirement for the in vitro response to TNP Ficoll: a thymic independent antigen. J Immunol. 1976 Jun;116(6):1579–1581. [PubMed] [Google Scholar]
  7. Fidler I. J. Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines. Science. 1980 Jun 27;208(4451):1469–1471. doi: 10.1126/science.7384789. [DOI] [PubMed] [Google Scholar]
  8. Gillis S., Ferm M. M., Ou W., Smith K. A. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol. 1978 Jun;120(6):2027–2032. [PubMed] [Google Scholar]
  9. Hardt C., Röllinghoff M., Pfizenmaier K., Mosmann H., Wagner H. Lyt-23+ cyclophosphamide-sensitive T cells regulate the activity of an interleukin 2 inhibitor in vivo. J Exp Med. 1981 Aug 1;154(2):262–274. doi: 10.1084/jem.154.2.262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Harrison S. D., Jr, Denine E. P., Peckham J. C. Qualitative and quantitative toxicity of single and sequential sublethal doses of 5-fluorouracil in BDF mice. Cancer Treat Rep. 1978 Apr;62(4):533–545. [PubMed] [Google Scholar]
  11. Houghton J. A., Houghton P. J., Wooten R. S. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine. Cancer Res. 1979 Jul;39(7 Pt 1):2406–2413. [PubMed] [Google Scholar]
  12. Howell S. B., Wung W. E., Taetle R., Hussain F., Romine J. S. Modulation of 5-fluorouracil toxicity by allopurinol in man. Cancer. 1981 Sep 15;48(6):1281–1289. doi: 10.1002/1097-0142(19810915)48:6<1281::aid-cncr2820480603>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  13. Jacobs D. M., Morrison D. C. Stimulation of a T-independent primary anti-hapten response in vitro by TNP-lipopolysaccharide (TNP-LPS). J Immunol. 1975 Jan;114(1 Pt 2):360–364. [PubMed] [Google Scholar]
  14. Lubet R. A., Carlson D. E. Therapy of the murine plasmacytoma MOPC 104E: role of the immune response. J Natl Cancer Inst. 1978 Sep;61(3):897–903. [PubMed] [Google Scholar]
  15. Merluzzi V. J., Faanes R. B., Choi Y. S. Recovery of the capacity for cytotoxic T cell generation in cyclophosphamide-treated mice by the addition of LYT-1/2- helper cells. Int J Immunopharmacol. 1980;2(4):341–344. doi: 10.1016/0192-0561(80)90034-x. [DOI] [PubMed] [Google Scholar]
  16. Merluzzi V. J., Susskind B. M., Faanes R. B. Effect of cytarabine on cytotoxic T-cell development. Cancer Treat Rep. 1982 Mar;66(3):535–540. [PubMed] [Google Scholar]
  17. Moore M., Williams D. E. Contribution of host immunity to cyclophosphamide therapy of a chemically-induced murine sarcoma. Int J Cancer. 1973 Mar 15;11(2):358–368. doi: 10.1002/ijc.2910110213. [DOI] [PubMed] [Google Scholar]
  18. Nordman E., Saarimaa H., Toivanen A. The influence of 5-fluorouracil on cellular and humoral immunity in cancer patients. Cancer. 1978 Jan;41(1):64–69. doi: 10.1002/1097-0142(197801)41:1<64::aid-cncr2820410111>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  19. Ohta Y., Sueki K., Kitta K., Takemoto K., Ishitsuka H., Yagi Y. Comparative studies on the immunosuppressive effect among 5'-deoxy-5-fluorouridine, ftorafur, and 5-fluorouracil. Gan. 1980 Apr;71(2):190–196. [PubMed] [Google Scholar]
  20. Okada M., Klimpel G. R., Kuppers R. C., Henney C. S. The differentiation of cytotoxic T cells in vitro. I. Amplifying factor(s) in the primary response is Lyt 1 + cell dependent. J Immunol. 1979 Jun;122(6):2527–2533. [PubMed] [Google Scholar]
  21. PORTER E. H., BERRY R. J. THE EFFICIENT DESIGN OF TRANSPLANTABLE TUMOUR ASSAYS. Br J Cancer. 1963 Dec;17:583–595. doi: 10.1038/bjc.1963.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Papermaster B. W., Gilliland C. D., McEntire J. E., Smith M. E., Buchok S. J. Lymphokine-mediated immunotherapy studies in mouse tumor systems. Cancer. 1980 Mar 15;45(5 Suppl):1248–1253. doi: 10.1002/1097-0142(19800315)45:5+<1248::aid-cncr2820451335>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  23. Plate J. M. Soluble factors substitute for T-T-cell collaboration in generation of T-killer lymphocytes. Nature. 1976 Mar 25;260(5549):329–331. doi: 10.1038/260329a0. [DOI] [PubMed] [Google Scholar]
  24. Radley J. M., Scurfield G. Effects of 5-fluorouracil on mouse bone marrow. Br J Haematol. 1979 Nov;43(3):341–351. doi: 10.1111/j.1365-2141.1979.tb03761.x. [DOI] [PubMed] [Google Scholar]
  25. Ryser J. E., Cerottini J. C., Brunner K. T. Generation of cytolytic T lymphocytes in vitro. IX. induction of secondary CTL responses in primary long-term MLC by supernatants from secondary MLC. J Immunol. 1978 Feb;120(2):370–377. [PubMed] [Google Scholar]
  26. Röllinghoff M., Starzinski-Powitz A., Pfizenmaier K., Wagner H. Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes. J Exp Med. 1977 Feb 1;145(2):455–459. doi: 10.1084/jem.145.2.455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Schmid F. A., Hutchison D. J., Otter G. M., Stock C. C. Deveopment of resistance to combinations of six antimetabolites in mice with L1210 leukemia. Cancer Treat Rep. 1976 Jan;60(1):23–27. [PubMed] [Google Scholar]
  28. Spiers A. S., Kasimis B. S., Janis M. G. High-dose intravenous infusions of 5-fluorouracil for refractory solid tumours-the HI-FU regimen. Clin Oncol. 1980 Mar;6(1):63–69. [PubMed] [Google Scholar]
  29. Stötter H., Rüde E., Wagner H. T cell factor (interleukin 2) allows in vivo induction of T helper cells against heterologous erythrocytes in athymic (nu/nu) mice. Eur J Immunol. 1980 Sep;10(9):719–722. doi: 10.1002/eji.1830100912. [DOI] [PubMed] [Google Scholar]
  30. Susskind B. M., Faanes R. B. Effects of gamma-irradiation on lymphocyte subpopulations participating in the development of the cytotoxic T lymphocyte response. J Immunol. 1981 Oct;127(4):1485–1489. [PubMed] [Google Scholar]
  31. Taswell C., MacDonald H. R., Cerottini J. C. Limiting dilution analysis of alloantigen-reactive T lymphocytes. II. Effect of cortisone and cyclophosphamide on cytolytic T lymphocyte precursor frequencies in the thymus. Thymus. 1979 Sep;1(1-2):119–131. [PubMed] [Google Scholar]
  32. Teller M. N., Faanes R. B. Association of host immunity with 5-fluorouracil-initiated cure of plasmacytoma LPC-1 in BALB/c mice. Cancer Res. 1980 Aug;40(8 Pt 1):2790–2795. [PubMed] [Google Scholar]
  33. Wagner H., Hardt C., Heeg K., Röllinghoff M., Pfizenmaier K. T-cell-derived helper factor allows in vivo induction of cytotoxic T cells in nu/nu mice. Nature. 1980 Mar 20;284(5753):278–278. doi: 10.1038/284278a0. [DOI] [PubMed] [Google Scholar]
  34. Wagner H., Röllinghoff M. T-T-cell interactions during the vitro cytotoxic allograft responses. I. Soluble products from activated Lyl+ T cells trigger autonomously antigen-primed Ly23+ T cells to cell proliferation and cytolytic activity. J Exp Med. 1978 Dec 1;148(6):1523–1538. doi: 10.1084/jem.148.6.1523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Wood H. B., Jr Selection of agents for the tumor screen of potential new antineoplastic drugs. Natl Cancer Inst Monogr. 1977 Mar;(45):15–35. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES